SMARCA4 and neoplasm: As such, pharmacological inhibition of SWI/SNF ATPases (e.g., SMARCA4/2 inhibitors and BRD9 degraders) disrupts chromatin accessibility at POU2F3 regulatory loci, leading to transcriptional reprogramming and impaired tumor growth [59].